Codes ATC:
L01AA06
EMLc
Indication
Rhabdomyosarcoma primary site
Code ICD11:
2C25.Z
INN
Ifosfamide
Type de médicament
Chemical agent
Type de liste
Liste complémentaire
(EML)
(EMLc)
(EMLc)
Formulations
Parenteral > General injections > IV:
500 mg in vial powder for injection ;
1 g in vial powder for injection ;
2 g in vial powder for injection
Sexe
Tous
Âge
Aussi recommandé pour les enfants
Équivalence thérapeutique
La recommandation concerne ce médicament spécifique
Renseignements sur le brevet
Patents have expired in most jurisdictions
Lire la suite
sur les brevets.
Résumé des preuves et recommandation du comité d'experts
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for ifosfamide on the complementary list of the EML for use in treatment protocols for rhabdomyosarcoma was specifically endorsed. Additionally, ifosfamide was included on the complementary list of the EMLc for this indication. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for rhabdomyosarcoma is attached.